Abstract:ID 93501 Poster Board 472 ST-elevation myocardial infarction (STEMI) is the most dramatic complication of coronary artery disease and is associated with a high morbidity and mortality rate worldwide. Immediate reperfusion is critical to restore blood flow to the heart, limit infarct size, and reduce the risk of post-STEMI complications, thereby improving long-term survival. However, reperfusion therapy itself is thought to eventually cause further damage to the myocardium, known as reperfusion injury, which enhances the already existing inflammatory response. This immune response can lead to adverse left ventricular remodelling and heart failure in the mid-and long term. Therefore, specific treatment targets are required to reduce excessive inflammation while maintaining immune defence. We have previously shown in 1,300 STEMI patients that immune cells, specifically T cells, are significantly decreased within minutes of reperfusion therapy, which may correlate closely with pathophysiological conditions. This significant reduction was observed in all cells expressing CX3CR1, the receptor for fractalkine. Fractalkine (FKN, CX3CL1) is a member of the chemokine family that facilitates the extravasation and recruitment of CX3CR1-expressing lymphocytes to sites of tissue inflammation. Thus, blocking fractalkine/CX3CR1 signaling is suggested as a promising anti-inflammatory strategy for the treatment of both acute and chronic cardiovascular disease. KAND567, a KANCERA AB drug candidate, is a small molecule, selective, non-competitive, allosteric antagonist of CX3CR1 and has been used as IMP (Investigational Medicinal Product) for this clinical phase IIa study in STEMI patients (ISRCTN 18402242). The aim of this project is to investigate the dynamic changes in immune cell count and CX3CR1 expression after intravenous and oral administration of KAND567 to STEMI patients undergoing primary percutaneous coronary intervention (PPCI). This study is a randomized, 2-arm, parallel-group, placebo-controlled, double-blind, multi-centre Phase IIa clinical trial, "FRACTAL Trial". Blood sampling was at nine-time points, including baseline (before IM administration), bolus (after IMP administration), 90 mins, 180 mins, 1 day, 3 days, 6 days, 30 days and 90 days., The leukocyte kinetics in 71 STEMI patients was analysed using flow cytometry. The highest CX3CR1 receptor density at baseline was observed in CD4 and CD8+T cell subsets. Following different time points, CX3CR1 MFI in the CD8+ compartment remained low until day 6. In addition, CX3CR1-expressing effector T cell subsets, monocytes and NK cells decreased 90 mins after administration of IMP and recovered rapidly for up to 24 hours. Effector T-cells drop substantially after reperfusion only in some patients. One possible explanation for this may be that KAND567 binds CX3CR1-expressing effector T-cell subsets, monocytes, and NK cells in the peripheral blood, preventing their migration to the heart and thus reducing the decrease in cell numbers in the peripheral blood. Another possible explanation could be that previously depleted cells return to circulation. This project was supported by British Heart Foundation and KANCERNA a.Pre-reperfusion expression of CX3CR1 on lymphocyte subsets

Tissue Kallikrein Preventing the Restenosis after Stenting of Symptomatic MCA Atherosclerotic Stenosis (KPRASS).

Tissue Kallikrein Prevents Restenosis after Stenting of Severe Atherosclerotic Stenosis of the Middle Cerebral Artery A Randomized Controlled Trial

A Multicenter, Randomized,double-Blinded and Placebo-Controlled Study of Acute Brain Infarction Treated by Humanurinary Kallidinogenase

Clinical Effect of Maixuekang Capsule on Long-Term Prognosis in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention

Stenting versus non-stenting treatment of intermediate stenosis culprit lesion in acute ST-segment elevation myocardial infarction: a multicenter randomized clinical trial.

A Phase IIa Clinical Trial of KAND567, Fractalkine Receptor Inhibitor, in Patients with ST-Elevation Acute Myocardial Infarction after Percutaneous Coronary Intervention

Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.

Tissue Kallikrein is Related to the Severity of Coronary Artery Disease

Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis

Tissue Kallikrein Promotes Neovascularization and Improves Cardiac Function by the Akt-glycogen Synthase Kinase-3Beta Pathway.

The Design and Rationale of a Clinical Trial Evaluating Limb Postconditioning in Young Patients with Intracranial Arterial Stenosis.

Tissue Kallikrein supplementation in ischemic phase protects the neurovascular unit and attenuates reperfusion-induced injury in ischemic stroke

Randomized Controlled Trial of Human Urinary Kallikrein in the Treatment of Acute Cerebral Infarction

China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): A New, Prospective, Multicenter, Randomized Controlled Trial in China

A clinical application study of a stent placement assessment

Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial

Treatment and Short-Term Follow-up of Symptomatic Atherosclerotic Intracranial Artery Stenosis by Stent-Assisted Angioplasty.

High Level of Serum Tissue Kallikrein is Associated with Favorable Outcome in Acute Ischemic Stroke Patients.

Kallikrein Promotes Endogenous Neuronal Stem Cell Proliferation, Mioration, and Selective Differentiation after Focal Cortical Infarction

Argatroban for preventing occlusion and restenosis after extracranial artery stenting.

Tissue Kallikrein and Kinin Infusion Rescues Failing Myocardium after Myocardial Infarction